Kezar Life Sciences (NASDAQ:KZR) Receives “Neutral” Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Kezar Life Sciences (NASDAQ:KZR) in a research note issued to investors on Monday, Benzinga reports.

Kezar Life Sciences Trading Up 2.8 %

Shares of NASDAQ:KZR opened at $0.89 on Monday. The company has a 50 day moving average of $0.65 and a 200-day moving average of $0.69. The company has a current ratio of 9.58, a quick ratio of 9.58 and a debt-to-equity ratio of 0.05. The firm has a market cap of $65.14 million, a P/E ratio of -0.64 and a beta of 0.21. Kezar Life Sciences has a twelve month low of $0.52 and a twelve month high of $1.14.

Kezar Life Sciences (NASDAQ:KZR) last announced its earnings results on Tuesday, August 13th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.04. As a group, analysts anticipate that Kezar Life Sciences will post -1.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kezar Life Sciences

Large investors have recently made changes to their positions in the business. Ikarian Capital LLC increased its stake in Kezar Life Sciences by 1.8% in the 1st quarter. Ikarian Capital LLC now owns 868,992 shares of the company’s stock worth $783,000 after purchasing an additional 15,601 shares in the last quarter. Fidelis Capital Partners LLC acquired a new stake in shares of Kezar Life Sciences during the 1st quarter valued at $25,000. Vanguard Group Inc. grew its holdings in shares of Kezar Life Sciences by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock valued at $2,790,000 after acquiring an additional 30,740 shares in the last quarter. Mackenzie Financial Corp acquired a new position in shares of Kezar Life Sciences in the second quarter worth $35,000. Finally, Acadian Asset Management LLC increased its stake in shares of Kezar Life Sciences by 3.6% in the second quarter. Acadian Asset Management LLC now owns 1,855,194 shares of the company’s stock worth $1,112,000 after acquiring an additional 64,356 shares during the last quarter. Institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.